US imposes 100% tariff on imported patented pharmaceuticals with exemptions for some countries and companies
Consensus Summary
The US government under Donald Trump has imposed a 100% tariff on patented pharmaceuticals manufactured outside the country, effective July 31, 2025, as part of a broader push to reshoring drug production. Australia, the UK, Japan, the EU, South Korea, Switzerland, and Liechtenstein have received lower tariff rates ranging from 10% to 15%, while Australia—despite being a close ally—faces the highest rate without a special deal. The tariff targets patented drugs but excludes generics and includes exemptions for plasma-derived therapies if they meet urgent US health needs or come from countries with trade deals. Australia’s largest pharmaceutical exporter, CSL, has significant US manufacturing capacity and is confident it will qualify for exemptions due to its existing US plants and ongoing $1.5 billion expansion. The Australian government, led by Health Minister Mark Butler, has firmly rejected US pressure to alter the country’s Pharmaceutical Benefits Scheme, which ensures affordable drug prices for Australians. Opposition Leader Angus Taylor has pledged to work with the government to secure exemptions for Australian exporters. The tariff is implemented under Section 232 of the Trade Expansion Act, avoiding the Supreme Court’s February ruling that struck down Trump’s broader 'Liberation Day' tariffs. The move reflects ongoing tensions over drug pricing, with the US seeking lower prices for American consumers compared to other countries, including Australia’s subsidized PBS system.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented drugs manufactured outside the US on June 2025 (Washington time).
- Australia exported approximately $US1.32 billion to $US1.91 billion worth of pharmaceuticals to the US in 2024 or 2025, with CSL being the largest exporter.
- CSL has manufacturing plants in the US (Illinois, North Carolina), Australia, and Europe, and announced a $US1.5 billion to $US2.2 billion expansion of its Illinois facility in March 2025.
- The tariff applies to patented drugs but not generic medicines, and is enacted under Section 232 of the Trade Expansion Act, unaffected by the Supreme Court’s February 2025 ruling on 'Liberation Day' tariffs.
- Companies moving production to the US can reduce tariffs to 20%, and tariffs can be set to zero if the US achieves 'most favoured nation' status on drug pricing from the exporting country.
- Japan, the EU, South Korea, Switzerland, and Liechtenstein have negotiated 15% tariffs, while the UK has a 10% tariff with potential for further reduction.
- The tariff will take effect on July 31, 2025, with large companies having 120 days and smaller companies 180 days to comply or negotiate exemptions.
- Australia’s Pharmaceutical Benefits Scheme (PBS) ensures lower drug prices for Australians, which the US administration has criticized as undermining 'most favoured nation' pricing principles.
- Health Minister Mark Butler stated Australia would not negotiate changes to the PBS, calling it 'world leading' and 'not for sale'.
- Opposition Leader Angus Taylor expressed concern and pledged to work with the government to overturn or exempt Australian exporters from the tariffs.
Points of Difference
Details reported by only one source:
- The White House official explicitly stated 'Australia does not have a special pharma tariff rate' despite being a close ally.
- The tariff adjustment for steel components was mentioned: products with less than 15% steel would have zero additional tariff, while those exceeding 15% would face a 25% tariff on the total value.
- The tariff announcement was timed to mark one year since Trump’s 'Liberation Day' tariffs in February 2025.
- Medicines Australia stated that 'most favoured nation' rules are already hampering imports to Australia, with new medicines launches being scrutinized and delayed due to low Australian prices.
- The tariff is invoked under national security powers, with the executive order stating it is necessary to address 'threatened impairment of the national security' from pharmaceutical imports.
- A senior administration official claimed 'too many drugs driven by US research and development are now produced abroad,' making the US 'beholden to these other countries.'
- The ABC reported Trump previously suggested the tariff could be as high as 200%, but it was ultimately set at 100%.
- The ABC noted CSL had previously stated in September 2024 it did 'not expect any material impact' from the tariff.
- The Guardian emphasized that the US administration is trying to force manufacturers to agree to drug-pricing deals or commit to domestic production, framing it as a pressure tactic.
- The Guardian included a quote from Communications Minister Anika Wells: 'The Australian PBS is not for sale. We will not be compromising on our PBS.'
- The article explicitly stated the tariff applies to patented products, not generic medicines, and included a direct quote from Health Minister Mark Butler: 'That won’t have an impact on the price of our drugs here, but it certainly is going to create uncertainty for those exporters.'
- The SMH repeated the same details as THEAGE, with no additional unique information.
Contradictions
Conflicting information between sources:
- The Guardian and SBS both report that 'most favoured nation' rules are impacting Australian pharmaceutical imports, but THEAGE and ABC do not explicitly mention this as a direct consequence of the tariff announcement.
- The ABC states Trump previously suggested the tariff could be as high as 200%, but THEAGE and SBS do not mention this specific figure.
- The Guardian and SBS emphasize the US administration’s pressure on Australia to change its PBS, while THEAGE and ABC focus more on the tariff’s implementation details and exemptions without highlighting this pressure as prominently.
Source Articles
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....